Evaluating and Predicting Human Cytochrome P450 Enzyme Induction

Drug Metabolism Handbook: Concepts and Applications

Volumn , Issue , 2008, Pages 359-389

  Sinz, Michael ^a   Kim, Sean ^a   Ferguson, Stephen ^b   Lecluyse, Edward ^b  

^a BRISTOL MYERS SQUIBB   (United States)

^b CellzDirect Inc   (United States)

Author keywords

Clinical drug interaction studies; Evaluating and predicting human cytochrome P450 enzyme induction; Immortalized human hepatocyte cell lines Fa2N 4

Indexed keywords

EID: 84889844500     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470439265.ch15     Document Type: Chapter

References (145)

1. Abdel-Razzak, Z., Corcos, L., Fautrel, A., Guillouzo, A. (1995). Interleukin-1 beta antagonizes phenobarbital induction of several major cytochromes P450 in adult rat hepatocytes in primary culture. FEBS Lett., 366 (2-3), 159-164.
2. Aiba, T., Susa, M., Fukumori, S., Hashimoto, Y. (2005). The effects of culture conditions on CYP3A4 and MDR1 mRNA induction by 1alpha,25-dihydroxyvitamin D(3) in human intestinal cell lines, Caco-2 and LS180. Drug Metab. Pharmacokinet., 20 (4), 268-274.
3. Akiyama, I., Tomiyama, K., Sakaguchi, M. et al. (2004). Expression of CYP3A4 by an immortalized human hepatocyte line in a three-dimensional culture using a radial-flow bioreactor. Int. J. Mol. Med., 14 (4), 663-668.
4. Alison, M.R., Poulsom, R., Jeffery, R. et al. (2000). Hepatocytes from non-hepatic adult stem cells. Nature, 406 (6793), 257.
5. Aninat, C., Piton, A., Glaise, D. et al. (2006). Expression of cytochromes P450, conjugating enzymes and nuclear receptors in human hepatoma HepaRG cells. Drug Metab. Dispos., 34 (1), 75-83.
6. Auerbach, S.S., Stoner, M.A., Su, S., Omiecinski, CJ. (2005). Retinoid X receptor-a lpha-d ependent transactivation by a naturally occurring structural variant of human constitutive androstane receptor (NR1I3). Mol. Pharmacol., 68 (5), 1239-1253.
7. Baliharova, V., Skalova, L., Maas, R.F., De Vrieze, G., Bull, S., Fink-Gremmels, J. (2003). The effects of benzimidazole anthelmintics on P4501A in rat hepatocytes and HepG2 cells. Res. Vet. Sci., 75 (1), 61-69.
8. Bapiro, T.E., Andersson, T.B., Otter, C., Hasler, J.A., Masimirembwa, C.M. (2002). Cytochrome P450 1A1/2 induction by antiparasitic drugs: dose-dependent increase in ethoxyresorufin O-deethylase activity and mRNA caused by quinine, primaquine and albendazole in HepG2 cells. Eur. J. Clin. Pharmacol., 58 (8), 537-542.
9. Bertilsson, L., Hojer, B., Tybring, G., Osterloh, J., Rane, A. (1980). Autoinduction of carbamazepine metabolism in children examined by a stable isotope technique. Clin. Pharmacol. Ther., 27 (1), 83-88.
10. Bi, Y.A., Kazolias, D., Duignan, D.B. (2006). Use of cryopreserved human hepatocytes in sandwich culture to measure hepatobiliary transport. Drug Metab. Dispos., 34 (9), 1658-1665.
11. Brandin, H., Viitanen, E., Myrberg, O., Arvidsson, A.K. (2007). Effects of herbal medicinal products and food supplements on induction of CYP1A2, CYP3A4 and MDR1 in the human colon carcinoma cell line LS180. Phytother. Res., 21 (3), 239-244.
12. Brown, R.R., Miller, J.A., Miller, E.C. (1954). The metabolism of methylated aminoazo dyes. IV. Dietary factors enhancing demethylation in vitro. J. Biol. Chem., 209 (1), 211-222.
13. Bullock, P., Pearce, R., Draper, A. et al. (1995). Induction of liver microsomal cytochrome P450 in cynomolgus monkeys. Drug. Metab. Dispos., 23 (7), 736-748.
14. Cascio, S.M. (2001). Novel strategies for immortalization of human hepatocytes. Artif. Organs, 25 (7), 529-538.
15. Chang, T.K., Waxman, D.J. (2006). Synthetic drugs and natural products as modulators of constitutive androstane receptor (CAR) and pregnane X receptor (PXR). Drug Metab. Rev., 38 (1-2), 51-73.
16. Chen, J., Nikolova-Karakashian, M., Merrill, A.H., Jr, Morgan, E.T. (1995a). Regulation of cytochrome P450 2C11 (CYP2C11) gene expression by interleukin-1, sphingomyelin hydrolysis, and ceramides in rat hepatocytes. J. Biol. Chem., 270 (42), 25233-25238.
17. Chen, J.Q., Strom, A., Gustafsson, J.A., Morgan, E.T. (1995b). Suppression of the constitutive expression of cytochrome P-450 2C11 by cytokines and interferons in primary cultures of rat hepatocytes: comparison with induction of acute-phase genes and demonstration that CYP2C11 promoter sequences are involved in the suppressive response to interleukins 1 and 6. Mol. Pharmacol., 47 (5), 940-947.
18. Chen, Y., Ferguson, S.S., Negishi, M., Goldstein, J.A. (2003). Identification of constitutive androstane receptor and glucocorticoid receptor binding sites in the CYP2C19 promoter. Mol. Pharmacol., 64 (2), 316-324.
19. Chen, Y., Ferguson, S.S., Negishi, M., Goldstein, J.A. (2004). Induction of human CYP2C9 by rifampicin, hyperforin, and phenobarbital is mediated by the pregnane X receptor. J. Pharmacol. Exp. Ther., 308 (2), 495-501.
20. Conney, A.H. (1967). Pharmacological implications of microsomal enzyme induction. Pharmacol. Rev., 19 (3), 317-366.
21. Daujat, M., Peryt, B., Lesca, P., Fourtanier, G., Domergue, J., Maurel, P. (1992). Omeprazole, an inducer of human CYP1A1 and 1A2, is not a ligand for the Ah receptor. Biochem. Biophys. Res. Commun., 188 (2), 820-825.
22. Dickins, M. (2004). Induction of cytochromes P450. Curr. Top. Med. Chem., 4 (16), 1745-1766.
23. Dilger, K., Zheng, Z., Klotz, U. (1999). Lack of drug interaction between omeprazole, lansoprazole, pantoprazole and theophylline. Br. J. Clin. Pharmacol., 48 (3), 438-444.
24. Dvorak, Z., Modriansky, M., Pichard-Garcia, L. et al. (2003). Colchicine down-regulates cytochrome P450 2B6, 2C8, 2C9, and 3A4 in human hepatocytes by affecting their glucocorticoid receptor-mediated regulation. Mol. Pharmacol., 64 (1), 160-169.
25. Ek, M., Soderdahl, T., Kuppers-Munther, B. et al. (2007). Expression of drug metabolizing enzymes in hepatocyte-like cells derived from human embryonic stem cells. Biochem. Pharmacol., 74 (3), 496-503.
26. Ekins, S., Chang, C., Mani, S. et al. (2007). Human pregnane x receptor antagonists and agonists define molecular requirements for different binding sites. Mol. Pharmacol., 72 (3), 592-603.
27. El-Sankary, W., Gibson, G.G., Ayrton, A., Plant, N. (2001). Use of a reporter gene assay to predict and rank the potency and efficacy of CYP3A4 inducers. Drug Metab. Dispos., 29 (11), 1499-1504.
28. Engman, H.A., Lennernas, H., Taipalensuu, J., Otter, C., Leidvik, B., Artursson, P. (2001). CYP3A4, CYP3A5, and MDR1 in human small and large intestinal cell lines suitable for drug transport studies. J. Pharm. Sci., 90 (11), 1736-1751.
29. Fabre, N., Arrivet, E., Trancard, J. et al. (2003). A new hepatoma cell line for toxicity testing at repeated doses. Cell Biol. Toxicol., 19 (2), 71-82.
30. Faucette, S.R., Sueyoshi, T., Smith, C.M., Negishi, M., LeCluyse, E.L., Wang, H. (2006). Differential regulation of hepatic CYP2B6 and CYP3A4 genes by constitutive androstane receptor but not pregnane X receptor. J. Pharmacol. Exp. Ther., 317 (3), 1200-1209.
31. Faucette, S.R., Zhang, T.C., Moore, R. et al. (2007). Relative activation of human pregnane X receptor versus constitutive androstane receptor defines distinct classes of CYP2B6 and CYP3A4 inducers. J. Pharmacol. Exp. Ther., 320 (1), 72-80.
32. FDA (1999). Guidance for industry in vivo drug metabolism/drug interaction studies - study, design, data analysis, and recommendations for dosing and labelling.
33. FDA (2006). FDA Draft Guideline: drug interaction studies - study design, data analysis, and implications for dosing and labeling.
34. Ferguson, S.S., Chen, Y., LeCluyse, E.L., Negishi, M., Goldstein, JA. (2005). Human CYP2C8 is transcriptionally regulated by the nuclear receptors constitutive androstane receptor, pregnane X receptor, glucocorticoid receptor, and hepatic nuclear factor 4alpha. Mol. Pharmacol., 68 (3), 747-757.
35. Gomez-Lechon, M.J., Donato, T., Jover, R. et al. (2001). Expression and induction of a large set of drug-metabolizing enzymes by the highly differentiated human hepatoma cell line BC2. Eur. J. Biochem., 268 (5), 1448-1459.
36. Gonzalez, F.J. (2007). The 2006 Bernard B. Brodie Award Lecture. Cyp2e1. Drug Metab. Dispos., 35 (1), 1-8.
37. Goodwin, B., Hodgson, E., Liddle, C. (1999). The orphan human pregnane X receptor mediates the transcriptional activation of CYP3A4 by rifampicin through a distal enhancer module. Mol. Pharmacol., 56 (6), 1329-1339.
38. Gripon, P., Rumin, S., Urban, S. et al. (2002). Infection of a human hepatoma cell line by hepatitis B virus. Proc. Natl. Acad. Sci. U.S.A., 99 (24), 15655-15660.
39. Guillouzo, A., Corlu, A., Aninat, C., Glaise, D., Morel, F., Guguen-Guillouzo, C. (2007). The human hepatoma HepaRG cells: a highly differentiated model for studies of liver metabolism and toxicity of xenobiotics. Chem Biol. Interact., 168 (1), 66-73.
40. Hahn, W.C. (2002). Immortalization and transformation of human cells. Mol. Cells, 13 (3), 351-361.
41. Hamilton, G.A., Jolley, S.L., Gilbert, D., Coon, D.J., Barros, S., LeCluyse, E.L. (2001). Regulation of cell morphology and cytochrome P450 expression in human hepatocytes by extracellular matrix and cell-cell interactions. Cell Tissue Res., 306 (1), 85-99.
42. Handschin, C., Podvinec, M., Meyer, U.A. (2003). In silico approaches, and in vitro and in vivo experiments to predict induction of drug metabolism. Drug News Perspect., 16 (7), 423-434.
43. Hariparsad, N., Carr, B., Evers, R., Chu, X. (2008). Comparison of immortalized Fa2N-4 cells and human hepatocytes as in vitro models for cytochrome P450 induction. Drug Metab. Dispos., 36 (6), 1046-1055.
44. Harmsen, S., Meijerman, I., Beijnen, J.H., Schellens, J.H. (2007). The role of nuclear receptors in pharmacokinetic drug-drug interactions in oncology. Cancer Treat. Rev., 33 (4), 369-380.
45. Hewitt, N.J., Hewitt, P. (2004). Phase I and II enzyme characterization of two sources of HepG2 cell lines. Xenobiotica, 34 (3), 243-256.
46. Hewitt, N.J., de Kanter, R., LeCluyse, E. (2007). Induction of drug metabolizing enzymes: a survey of in vitro methodologies and interpretations used in the pharmaceutical industry - do they comply with FDA recommendations? Chem. Biol. Interact., 168 (1), 51-65.
47. Hewitt, N.J., Lechon, M.J., Houston, J.B. et al. (2007). Primary hepatocytes: current understanding of the regulation of metabolic enzymes and transporter proteins, and pharmaceutical practice for the use of hepatocytes in metabolism, enzyme induction, transporter, clearance, and hepatotoxicity studies. Drug Metab. Rev., 39 (1), 159-234.
48. Honkakoski, P., Sueyoshi, T., Negishi, M. (2003). Drug-activated nuclear receptors CAR and PXR. Ann. Med., 35 (3), 172-182.
49. Hu, W., Sorrentino, C., Denison, M.S., Kolaja, K., Fielden, M.R. (2007). Induction of cyp1a1 is a nonspecific biomarker of aryl hydrocarbon receptor activation: results of large scale screening of pharmaceuticals and toxicants in vivo and in vitro. Mol. Pharmacol., 71 (6), 1475-1486.
50. Iwanari, M., Nakajima, M., Kizu, R., Hayakawa, K., Yokoi, T. (2002). Induction of CYP1A1, CYP1A2, and CYP1B1 mRNAs by nitropolycyclic aromatic hydrocarbons in various human tissue-derived cells: chemical-, cytochrome P450 isoform-, and cell-specific differences. Arch. Toxicol., 76 (5-6), 287-298.
51. Jackson, J.P., Ferguson, S.S., Moore, R., Negishi, M., Goldstein, J.A. (2004). The constitutive active/androstane receptor regulates phenytoin induction of Cyp2c29. Mol. Pharmacol., 65 (6), 1397-1404.
52. Jackson, J.P., Ferguson, S.S., Negishi, M., Goldstein, J.A. (2006). Phenytoin induction of the cyp2c37 gene is mediated by the constitutive androstane receptor. Drug Metab. Dispos., 34 (12), 2003-2010.
53. Jacobson, L., Middleton, B., Holmgren, J. et al. (2007). An optimized automated assay for determination of metabolic stability using hepatocytes: assay validation, variance component analysis, and in vivo relevance. Assay Drug Dev. Technol., 5 (3), 403-415.
54. de Jonge, M.E., Huitema, A.D., van Dam, S.M., Beijnen, J.H., Rodenhuis, S. (2005). Significant induction of cyclophosphamide and thiotepa metabolism by phenytoin. Cancer Chemother. Pharmacol., 55 (5), 507-510.
55. Kato, M., Chiba, K., Horikawa, M., Sugiyama, Y. (2005). The quantitative prediction of in vivo enzyme-induction caused by drug exposure from in vitro information on human hepatocytes. Drug Metab. Pharmacokinet., 20 (4), 236-243.
56. Katoh, M., Matsui, T., Nakajima, M. et al. (2005a). In vivo induction of human cytochrome P450 enzymes expressed in chimeric mice with humanized liver. Drug Metab. Dispos., 33 (6), 754-763.
57. Katoh, M., Watanabe, M., Tabata, T. et al. (2005b). In vivo induction of human cytochrome P450 3A4 by rifabutin in chimeric mice with humanized liver. Xenobiotica, 35 (9), 863-875.
58. Kawamoto, T., Sueyoshi, T., Zelko, I., Moore, R., Washburn, K., Negishi, M. (1999). Phenobarbital-responsive nuclear translocation of the receptor CAR in induction of the CYP2B gene. Mol. Cell. Biol., 19 (9), 6318-6322.
59. Kliewer, S.A., Goodwin, B., Willson, T.M. (2002). The nuclear pregnane X receptor: a key regulator of xenobiotic metabolism. Endocr. Rev., 23 (5), 687-702.
60. Kobayashi, N., Fujiwara, T., Westerman, K.A. et al. (2000). Prevention of acute liver failure in rats with reversibly immortalized human hepatocytes. Science, 287 (5456), 1258-1262.
61. Kodama, S., Koike, C., Negishi, M., Yamamoto, Y. (2004). Nuclear receptors CAR and PXR cross talk with FOXO1 to regulate genes that encode drug-metabolizing and gluconeogenic enzymes. Mol. Cell. Biol., 24 (18), 7931-7940.
62. Lagasse, E., Connors, H., Al-Dhalimy, M. et al. (2000). Purified hematopoietic stem cells can differentiate into hepatocytes in vivo. Nat. Med., 6 (11), 1229-1234.
63. Le Jossic, C., Glaise, D., Corcos, L. et al. (1996). trans-Acting factors, detoxication enzymes and hepatitis B virus replication in a novel set of human hepatoma cell lines. Eur. J. Biochem., 238 (2), 400-409.
64. Le Vee, M., Jigorel, E., Glaise, D., Gripon, P., Guguen-Guillouzo, C., Fardel, O. (2006). Functional expression of sinusoidal and canalicular hepatic drug transporters in the differentiated human hepatoma HepaRG cell line. Eur. J. Pharm. Sci., 28 (1-2), 109-117.
65. LeCluyse, E.L., Alexandre, E., Hamilton, G.A. et al. (2005). Isolation and culture of primary human hepatocytes. Methods Mol. Biol., 290, 207-229.
66. LeCluyse, E.L., Madan, A., Hamilton, G., Carroll, K., DeHaan, R., Parkinson, A. (2000). Expression and regulation of cytochrome P450 enzymes in primary cultures of human hepatocytes. J. Biochem. Mol. Toxicol., 14 (4), 177-188.
67. Lee, K.D., Kuo, T.K., Whang-Peng, J. et al. (2004). In vitro hepatic differentiation of human mesenchymal stem cells. Hepatology, 40 (6), 1275-1284.
68. Lemaire, G., de Sousa, G., Rahmani, R.A. (2004). PXR reporter gene assay in a stable cell culture system: CYP3A4 and CYP2B6 induction by pesticides. Biochem. Pharmacol., 68 (12), 2347-2358.
69. Li, Q., Sai, Y., Kato, Y., Tamai, I., Tsuji, A. (2003). Influence of drugs and nutrients on transporter gene expression levels in Caco-2 and LS180 intestinal epithelial cell lines. Pharm. Res., 20 (8), 1119-1124.
70. Luo, G., Cunningham, M., Kim, S. et al. (2002). CYP3A4 induction by drugs: correlation between a pregnane X receptor reporter gene assay and CYP3A4 expression in human hepatocytes. Drug Metab. Dispos., 30 (7), 795-804.
71. Luo, G., Lin, J., Fiske, W.D. et al. (2003). Concurrent induction and mechanism-based inactivation of CYP3A4 by an L-valinamide derivative. Drug Metab. Dispos., 31 (9), 1170-1175.
72. Ma, J.D., Nafziger, A.N., Rhodes, G., Liu, S., Bertino, J.S., Jr (2006a). Duration of pleconaril effect on cytochrome P450 3A activity in healthy adults using the oral biomarker midazolam. Drug Metab. Dispos., 34 (5), 783-785.
73. Ma, J.D., Nafziger, A.N., Rhodes, G., Liu, S., Gartung, A.M., Bertino, J.S., Jr (2006b). The effect of oral pleconaril on hepatic cytochrome P450 3A activity in healthy adults using intravenous midazolam as a probe. J. Clin. Pharmacol., 46 (1), 103-108.
74. McGinnity, D.F., Berry, A.J., Kenny, J.R., Grime, K., Riley, R.J. (2006). Evaluation of time-dependent cytochrome P450 inhibition using cultured human hepatocytes. Drug Metab. Dispos., 34 (8), 1291-1300.
75. McNeish, J. (2004). Embryonic stem cells in drug discovery. Nat. Rev. Drug Discov., 3 (1), 70-80.
76. Malmstrom, K., Schwartz, J., Reiss, T.F. et al. (1998). Effect of montelukast on single-dose theophylline pharmacokinetics. Am. J. Ther., 5 (3), 189-195.
77. Mandal, P.K. (2005). Dioxin: a review of its environmental effects and its aryl hydrocarbon receptor biology. J. Comp. Physiol. [B], 175 (4), 221-230.
78. Marion, T.L., Leslie, E.M., Brouwer, K.L. (2007). Use of sandwich-cultured hepatocytes to evaluate impaired bile acid transport as a mechanism of drug-induced hepatotoxicity. Mol. Pharm., 4 (6), 911-918.
79. Medina-Diaz, I.M., Arteaga-Illan, G., de Leon, M.B. et al. (2007). Pregnane X receptor-dependent induction of the CYP3A4 gene by o,p ′-1,1,1,-trichloro-2,2-bis (p-chlorophenyl)ethane. Drug Metab. Dispos., 35 (1), 95-102.
80. Medina-Diaz, I.M., Elizondo, G. (2005). Transcriptional induction of CYP3A4 by o,p ′-DDT in HepG2 cells. Toxicol. Lett., 157 (1), 41-47.
81. Mills, J.B., Rose, K.A., Sadagopan, N., Sahi, J., de Morais, S.M. (2004). Induction of drug metabolism enzymes and MDR1 using a novel human hepatocyte cell line. J. Pharmacol. Exp. Ther., 309 (1), 303-309.
82. Mueller, S.C., Majcher-Peszynska, J., Uehleke, B. et al. (2006). The extent of induction of CYP3A by St. John's wort varies among products and is linked to hyperforin dose. Eur J. Clin. Pharmacol., 62 (1), 29-36.
83. Nishimura, M., Imai, T., Morioka, Y., Kuribayashi, S., Kamataki, T., Naito, S. (2004). Effects of NO-1886 (Ibrolipim), a lipoprotein lipase-promoting agent, on gene induction of cytochrome P450s, carboxylesterases, and sulfotransferases in primary cultures of human hepatocytes. Drug Metab. Pharmacokinet., 19 (6), 422-429.
84. Nishimura, M., Koeda, A., Suganuma, Y. et al. (2007). Comparison of inducibility of CYP1A and CYP3A mRNAs by prototypical inducers in primary cultures of human, cynomolgus monkey, and rat hepatocytes. Drug Metab. Pharmacokinet., 22 (3), 178-186.
85. Nishimura, M., Yokoi, T., Tateno, C. et al. (2005). Induction of human CYP1A2 and CYP3A4 in primary culture of hepatocytes from chimeric mice with humanized liver. Drug Metab. Pharmacokinet., 20 (2), 121-126.
86. O'Connor, J.E., Martinez, A., Castell, J.V., Gomez-Lechon, M.J. (2005). Multiparametric characterization by flow cytometry of flow-sorted subpopulations of a human hepatoma cell line useful for drug research. Cytometry A, 63 (1), 48-58.
87. Okitsu, T., Kobayashi, N., Jun, H.S. et al. (2004). Transplantation of reversibly immortalized insulin-secreting human hepatocytes controls diabetes in pancreatectomized pigs. Diabetes, 53 (1), 105-112.
88. Omura, T., Sato, R. (1962). A new cytochrome in liver microsomes. J. Biol. Chem., 237, 1375-1376.
89. Park, J.Y., Kim, K.A., Kang, M.H., Kim, S.L., Shin, J.G. (2004). Effect of rifampin on the pharmacokinetics of rosiglitazone in healthy subjects. Clin. Pharmacol. Ther., 75 (3), 157-162.
90. Pascussi, J.M., Drocourt, L., Gerbal-Chaloin, S., Fabre, J.M., Maurel, P., Vilarem, M.J. (2001). Dual effect of dexamethasone on CYP3A4 gene expression in human hepatocytes. Sequential role of glucocorticoid receptor and pregnane X receptor. Eur. J. Biochem., 268 (24), 6346-6358.
91. Petersen, B.E., Bowen, W.C., Patrene, K.D. et al. (1999). Bone marrow as a potential source of hepatic oval cells. Science, 284 (5417), 1168-1170.
92. Pouton, C.W., Haynes, J.M. (2005). Pharmaceutical aspplications of embryonic stem cells. Adv. Drug Deliv. Rev., 57 (13), 1918-1934.
93. Pouton, C.W., Haynes, J.M. (2007). Embryonic stem cells as a source of models for drug discovery. Nat. Rev. Drug Discov., 6 (8), 605-616.
94. Prueksaritanont, T., Kuo, Y., Tang, C. et al. (2006). In vitro and in vivo CYP3A64 induction and inhibition studies in rhesus monkeys: a preclinical approach for CYP3A-mediated drug interaction studies. Drug Metab. Dispos., 34 (9), 1546-1555.
95. Qatanani, M., Moore, DD. (2005). CAR, the continuously advancing receptor, in drug metabolism and disease. Curr. Drug Metab., 6 (4), 329-339.
96. Raucy, J.L. (2003). Regulation of CYP3A4 expression in human hepatocytes by pharmaceuticals and natural products. Drug Metab. Dispos., 31 (5), 533-539.
97. Raucy, J.L., Lasker, J., Ozaki, K., Zoleta, V. (2004). Regulation of CYP2E1 by ethanol and palmitic acid and CYP4A11 by clofibrate in primary cultures of human hepatocytes. Toxicol. Sci., 79 (2), 233-241.
98. Raucy, J.L., Mueller, L., Duan, K., Allen, S.W., Strom, S., Lasker, J.M. (2002). Expression and induction of CYP2C P450 enzymes in primary cultures of human hepatocytes. J. Pharmacol. Exp. Ther., 302 (2), 475-482.
99. Reinach, B., de Sousa, G., Dostert, P., Ings, R., Gugenheim, J., Rahmani, R. (1999). Comparative effects of rifabutin and rifampicin on cytochromes P450 and UDP-glucuronosyl-transferases expression in fresh and cryopreserved human hepatocytes. Chem. Biol. Interact., 121 (1), 37-48.
100. Rencurel, F., Stenhouse, A., Hawley, S.A. et al. (2005). AMP-activated protein kinase mediates phenobarbital induction of CYP2B gene expression in hepatocytes and a newly derived human hepatoma cell line. J. Biol. Chem., 280 (6), 4367-4373.
101. Ripp, S.L., Mills, J.B., Fahmi, O.A. et al. (2006). Use of immortalized human hepatocytes to predict the magnitude of clinical drug-drug interactions caused by CYP3A4 induction. Drug Metab. Dispos., 34 (10), 1742-1748.
102. Rowland, M., Tozer, T.N. (1988). Clinical Pharmacokinetics: Concepts and Applications, Lea & Febiger, Philadelphia.
103. Roymans, D., Annaert, P., Van Houdt, J. et al. (2005). Expression and induction potential of cytochromes P450 in human cryopreserved hepatocytes. Drug Metab. Dispos., 33 (7), 1004-1016.
104. Runge, D., Michalopoulos, G.K., Strom, S.C., Runge, D.M. (2000). Recent advances in human hepatocyte culture systems. Biochem. Biophys. Res. Commun., 274 (1), 1-3.
105. Sahi, J., Milad, M.A., Zheng, X. et al. (2003). Avasimibe induces CYP3A4 and multiple drug resistance protein 1 gene expression through activation of the pregnane X receptor. J. Pharmacol. Exp. Ther., 306 (3), 1027-1034.
106. Schehrer, L., Regan, J.D., Westendorf, J. (2000). UDS induction by an array of standard carcinogens in human and rodent hepatocytes: effect of cryopreservation. Toxicology, 147 (3), 177-191.
107. Schmiedlin-Ren, P., Thummel, K.E., Fisher, J.M., Paine, M.F., Lown, K.S., Watkins, P.B. (1997). Expression of enzymatically active CYP3A4 by Caco-2 cells grown on extracellular matrix-coated permeable supports in the presence of 1alpha,25-dihydroxyvitamin D3. Mol. Pharmacol., 51 (5), 741-754.
108. Schmiedlin-Ren, P., Thummel, K.E., Fisher, J.M., Paine, M.F., Watkins, P.B. (2001). Induction of CYP3A4 by 1 alpha,25-dihydroxyvitamin D3 is human cell line-specific and is unlikely to involve pregnane X receptor. Drug Metab. Dispos., 29 (11), 1446-1453.
109. Schuetz, E.G., Beck, W.T., Schuetz, J.D. (1996). Modulators and substrates of P-glycoprotein and cytochrome P4503A coordinately up-regulate these proteins in human colon carcinoma cells. Mol. Pharmacol., 49 (2), 311-318.
110. Schwartz, R.E., Reyes, M., Koodie, L. et al. (2002). Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte-like cells. J. Clin. Invest., 109 (10), 1291-1302.
111. Shadle, C.R., Lee, Y., Majumdar, A.K. et al. (2004). Evaluation of potential inductive effects of aprepitant on cytochrome P450 3A4 and 2C9 activity. J. Clin. Pharmacol., 44 (3), 215-223.
112. Shao, J., Stapleton, P.L., Lin, Y.S., Gallagher, E.P. (2007). Cytochrome p450 and glutathione S-transferase mRNA expression in human fetal liver hematopoietic stem cells. Drug Metab. Dispos., 35 (1), 168-175.
113. Shih, H., Pickwell, G.V., Guenette, D.K., Bilir, B., Quattrochi, L.C. (1999). Species differences in hepatocyte induction of CYP1A1 and CYP1A2 by omeprazole. Hum. Exp. Toxicol., 18 (2), 95-105.
114. Silva, J.M., Day, S.H., Nicoll-Griffith, D.A. (1999). Induction of cytochrome-P450 in cryopreserved rat and human hepatocytes. Chem. Biol. Interact., 121 (1), 49-63.
115. Simonsson, U.S., Jansson, B., Hai, T.N., Huong, D.X., Tybring, G., Ashton, M. (2003). Artemisinin autoinduction is caused by involvement of cytochrome P450 2B6 but not 2C9. Clin. Pharmacol. Ther., 74 (1), 32-43.
116. Sinz, M.W., Kim, S. (2006). Stem cells, immortalized cells and primary cells in ADMET assays. Drug Discov. Today Technol., 3 (1), 79-85.
117. Sinz, M.W., Kim, S., Zhu, Z. et al. (2006). Evaluation of 170 xenobiotics as transactivators of human pregnane X receptor (hPXR) and correlation to known CYP3A4 drug interactions. Curr. Drug Metab., 7 (4), 375-388.
118. Smith, C.M., Graham, R.A., Krol, W.L. et al. (2005). Differential UGT1A1 induction by chrysin in primary human hepatocytes and HepG2 Cells. J. Pharmacol. Exp. Ther., 315 (3), 1256-1264.
119. Soars, M.G., McGinnity, D.F., Grime, K., Riley, R.J. (2007). The pivotal role of hepatocytes in drug discovery. Chem. Biol. Interact., 168 (1), 2-15.
120. Stanley, L.A., Horsburgh, B.C., Ross, J., Scheer, N., Wolf, CR. (2006). PXR and CAR nuclear receptors which play a pivotal role in drug disposition and chemical toxicity. Drug Metab. Rev., 38 (3), 515-597.
121. Synold, T.W., Dussault, I., Forman, B.M. (2001). The orphan nuclear receptor SXR coordinately regulates drug metabolism and efflux. Nat. Med., 7 (5), 584-590.
122. Tateno, C., Yoshizane, Y., Saito, N. et al. (2004). Near completely humanized liver in mice shows human-type metabolic responses to drugs. Am. J. Pathol., 165 (3), 901-912.
123. Tirona, R.G., Kim, R.B. (2005). Nuclear receptors and drug disposition gene regulation. J. Pharm. Sci., 94 (6), 1169-1186.
124. Trubetskoy, O., Marks, B., Zielinski, T., Yueh, M.F., Raucy, J. (2005). A simultaneous assessment of CYP3A4 metabolism and induction in the DPX-2 cell line. Aaps. J., 7 (1), E6-13.
125. Tsutsui, M., Ogawa, S., Inada, Y. et al. (2006). Characterization of cytochrome P450 expression in murine embryonic stem cell-derived hepatic tissue system. Drug Metab. Dispos., 34 (4), 696-701.
126. Tucker, G.T., Houston, J.B., Huang, S.M. (2001). Optimizing drug development: strategies to assess drug metabolism/transporter interaction potential - toward a consensus. Pharm. Res., 18 (8), 1071-1080.
127. Vermeir, M., Annaert, P., Mamidi, R.N., Roymans, D., Meuldermans, W., Mannens, G. (2005). Cell-based models to study hepatic drug metabolism and enzyme induction in humans. Expert Opin. Drug Metab. Toxicol., 1 (1), 75-90.
128. Vignati, L.A., Bogni, A., Grossi, P., Monshouwer, M. (2004). A human and mouse pregnane X receptor reporter gene assay in combination with cytotoxicity measurements as a tool to evaluate species-specific CYP3A induction. Toxicology, 199 (1), 23-33.
129. Wada, K., Takada, M., Ueda, T. et al. (2007). Drug interactions between tacrolimus and phenytoin in Japanese heart transplant recipients: 2 case reports. Int. J. Clin. Pharmacol. Ther., 45 (9), 524-528.
130. Walle, T., Otake, Y., Galijatovic, A., Ritter, J.K., Walle, U.K. (2000). Induction of UDP-glucuronosyltransferase UGT1A1 by the flavonoid chrysin in the human hepatoma cell line hep G2. Drug Metab. Dispos., 28 (9), 1077-1082.
131. Wang, H., Faucette, S., Moore, R., Sueyoshi, T., Negishi, M., LeCluyse, E. (2004). Human constitutive androstane receptor mediates induction of CYP2B6 gene expression by phenytoin. J. Biol. Chem., 279 (28), 29295-29301.
132. Wang, H., Huang, H., Li, H. et al. (2007). Activated pregnenolone X-receptor is a target for ketoconazole and its analogs. Clin. Cancer Res., 13 (8), 2488-2495.
133. Wang, H., LeCluyse, E.L. (2003). Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin. Pharmacokinet., 42 (15), 1331-1357.
134. Watanabe, T., Shibata, N., Westerman, K.A. et al. (2003). Establishment of immortalized human hepatic stellate scavenger cells to develop bioartificial livers. Transplantation, 75 (11), 1873-1880.
135. Werner, A., Duvar, S., Muthing, J. et al. (1999). Cultivation and characterization of a new immortalized human hepatocyte cell line, HepZ, for use in an artificial liver support system. Ann. N. Y. Acad. Sci., 875, 364-368.
136. Westerink, W.M., Schoonen, W.G. (2007a). Phase II enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro, 21 (8), 1592-1602.
137. Westerink, W.M., Schoonen, W.G. (2007b). Cytochrome P450 enzyme levels in HepG2 cells and cryopreserved primary human hepatocytes and their induction in HepG2 cells. Toxicol. In Vitro, 21 (8), 1581-1591.
138. Wilkening, S., Stahl, F., Bader, A. (2003). Comparison of primary human hepatocytes and hepatoma cell line Hepg2 with regard to their biotransformation properties. Drug Metab. Dispos., 31 (8), 1035-1042.
139. Worboys, P.D., Carlile, D.J. (2001). Implications and consequences of enzyme induction on preclinical and clinical drug development. Xenobiotica, 31 (8-9), 539-556.
140. Youdim, K.A., Tyman, C.A., Jones, B.C., Hyland, R. (2007). Induction of cytochrome P450: assessment in an immortalized human hepatocyte cell line (Fa2N4) using a novel higher throughput cocktail assay. Drug Metab. Dispos., 35 (2), 275-282.
141. Zhang, H., Davis, C.D., Sinz, M.W., Rodrigues, A.D. (2007). Cytochrome P450 reaction-phenotyping:an industrial perspective. Expert Opin. Drug Metab. Toxicol., 3 (5), 667-687.
142. Zhou, C., Tabb, M.M., Sadatrafiei, A., Grun, F., Blumberg, B. (2004). Tocotrienols activate the steroid and xenobiotic receptor, SXR, and selectively regulate expression of its target genes. Drug Metab. Dispos., 32 (10), 1075-1082.
143. Zhu, W., Song, L., Zhang, H., Matoney, L., LeCluyse, E., Yan, B. (2000). Dexamethasone differentially regulates expression of carboxylesterase genes in humans and rats. Drug Metab. Dispos., 28 (2), 186-191.
144. Zhu, Z., Kim, S., Chen, T. et al. (2004). Correlation of high-throughput pregnane X receptor (PXR) transactivation and binding assays. J. Biomol. Screen, 9 (6), 533-540.
145. Zhu, Z., Puglisi, J., Connors, D. et al. (2007). Use of cryopreserved transiently transfected cells in high-throughput pregnane X receptor transactivation assay. J. Biomol. Screen, 12 (2), 248-254.